Annovis Bio, Inc. ANVS

Company Overview

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, particularly Alzheimer’s disease and Parkinson’s disease. The company operates within the biotechnology and central nervous system (CNS) therapeutics industries, with research centered on reducing neurotoxic proteins and improving neuronal function. Its primary product candidate is buntanetap, an orally administered small molecule designed to target multiple neurotoxic proteins associated with neurodegeneration, including amyloid-beta, tau, alpha-synuclein, and TDP-43. The company’s revenue profile has historically been driven by financing activities and collaboration-related funding rather than commercial product sales, as it remains in the clinical development stage.

The company positions itself around a multi-target therapeutic strategy intended to address common upstream mechanisms across neurodegenerative disorders rather than focusing on a single pathological protein. Annovis Bio was founded in 2008 by Dr. Maria L. Maccecchini and evolved from early-stage neuroscience research into a publicly traded biotechnology company listed on the NYSE American under the ticker ANVS. Public disclosures and clinical updates indicate that the company has concentrated its resources on advancing buntanetap through clinical trials for Alzheimer’s disease and Parkinson’s disease while exploring broader neurodegenerative applications.